Department of Microbiology and Parasitology, University of Navarra, C/Irunlarrea 1, 31008, Pamplona, Spain.
Microbiology Service, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
Int Microbiol. 2020 May;23(2):171-177. doi: 10.1007/s10123-019-00087-z. Epub 2019 Jun 19.
Presence of extended-spectrum β-lactamase (ESBL-E), AmpC-producing and carbapenemase-producing (CPE) Enterobacteriaceae has been observed not only in the clinical environment, but also in the out-of-hospital environment. The objective of this study was to isolate and characterize strains of ESBL, AmpC, and CPE present in feces of healthy carriers in Navarra (n = 125). Despite the fact that no CPE strains were isolated, 16% and 11.2% of the studied population were ESBL-E and AmpC carriers, respectively. No significant differences were found by gender or age; young people (5-18 years old) showed the highest ESBL-E prevalence (31.8%). The isolates corresponded to E. coli (57.1%), Enterobacter spp. (28.6%), and Citrobacter freundii (14.3%), and all strains showed multidrug-resistant profiles. High resistance against cephalosporins, penicillins, and monobactams, and sensitivity to carbapenems, quinolones, and aminoglycosides were observed. With respect to ESBL producers, 52.4% were CTX-M-type (19.0% CTX-M-14, 9.5% CTX-M-1, and 28.6% CTX-M-15) and 47.6% were TEM-type (38.1% TEM-171). These results confirm the extensive dissemination of these resistances among a healthy population and pose the need to implement control measures and strategies according to the One Health approach in order to prevent the increase of severe and untreatable infections in a not far future.
产超广谱β-内酰胺酶(ESBL-E)、产 AmpC 酶和产碳青霉烯酶(CPE)肠杆菌科不仅在临床环境中存在,也存在于院外环境中。本研究的目的是分离和鉴定纳瓦拉(Navarra)健康携带者粪便中存在的 ESBL、AmpC 和 CPE 菌株(n=125)。尽管未分离出 CPE 菌株,但 16%和 11.2%的研究人群分别为 ESBL-E 和 AmpC 携带者。性别或年龄无显著差异;年轻人(5-18 岁)ESBL-E 患病率最高(31.8%)。分离株分别为大肠埃希菌(57.1%)、肠杆菌属(28.6%)和弗氏柠檬酸杆菌(14.3%),所有菌株均表现出多药耐药谱。对头孢菌素、青霉素和单酰胺类药物高度耐药,对碳青霉烯类、喹诺酮类和氨基糖苷类药物敏感。关于 ESBL 生产者,52.4%为 CTX-M 型(19.0%CTX-M-14、9.5%CTX-M-1 和 28.6%CTX-M-15)和 47.6%为 TEM 型(38.1%TEM-171)。这些结果证实了这些耐药性在健康人群中的广泛传播,并提出了根据“One Health”方法实施控制措施和策略的必要性,以防止在不远的将来严重和无法治疗的感染增加。